Cover |
Feb. 18, 2022 |
|---|---|
| Cover [Abstract] | |
| Entity Registrant Name | ZIVO BIOSCIENCE, INC. |
| Entity Central Index Key | 0001101026 |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Entity Emerging Growth Company | false |
| Document Period End Date | Feb. 18, 2022 |
| Entity Incorporation State Country Code | NV |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Entity File Number | 000-30415 |
| Entity Tax Identification Number | 87-0699977 |
| Entity Address Address Line 1 | 21 East Long Lake Road |
| Entity Address Address Line 2 | Suite 100 |
| Entity Address City Or Town | Bloomfield Hills |
| Entity Address State Or Province | MI |
| Entity Address Postal Zip Code | 48304 |
| Local Phone Number | 452-9866 |
| City Area Code | 248 |
| Security 12b Title | Common Stock, par value $0.001 per share |
| Trading Symbol | ZIVO |
| Security Exchange Name | NASDAQ |
| Amendment Description | This Current Report on Form 8-K/A (“Amendment No. 1”) amends the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 25, 2022 (the “Initial Filing”) by Zivo Bioscience, Inc. (the “Company”). This Amendment No. 1 is being filed pursuant to Item 5.02(a)(3)(iii) of Form 8-K in order to file as an exhibit an email received from Andrew Dahl (“Dahl”), a former member of the Board of Directors of the Company (the “Board”), pursuant to the opportunity to respond to the Initial Filing granted to him under Item 5.02(a)(3)(ii) of Form 8-K. The information contained in this Amendment No. 1 supplements the information contained in the Initial Filing. |